Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG

被引:16
作者
Groenendaal, D.
Freijer, J.
de Mik, D.
Bouw, M. R.
Danhof, M.
de Lange, E. C. M.
机构
[1] Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Pharmacol, NL-2300 RA Leiden, Netherlands
[2] LAP&P Consultants BV, Leiden, Netherlands
[3] GlaxoSmithKline Inc, Clin Pharmacokinet, Harlow, Essex, England
关键词
morphine; P-glycoprotein; population pharmacokinetic-pharmacodynamic modelling; biophase distribution; EEG;
D O I
10.1038/sj.bjp.0707258
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and purpose: The aim was to investigate the influence of biophase distribution including P- glycoprotein ( Pgp) function on the pharmacokinetic- pharmacodynamic correlations of morphine's actions in rat brain. Experimental approach: Male rats received a 10- min infusion of morphine as 4mg kg(-1), combined with a continuous infusion of the Pgp inhibitor GF120918 or vehicle, 10 or 40 mg kg(-1). EEG signals were recorded continuously and blood samples were collected. Key results: Profound hysteresis was observed between morphine blood concentrations and effects on the EEG. Only the termination of the EEG effect was influenced by GF120918. Biophase distribution was best described with an extended catenary biophase distribution model, with a sequential transfer and effect compartment. The rate constant for transport through the transfer compartment ( k(1e)) was 0.038 min(-1), being unaffected by GF120918. In contrast, the rate constant for the loss from the effect compartment ( k(eo)) decreased 60% after GF120918. The EEG effect was directly related to concentrations in the effect compartment using the sigmoidal E-max model. The values of the pharmacodynamic parameters E-o, E-max, EC50 and Hill factor were 45.0 mu V, 44.5 mu V, 451 ng ml(-1) and 2.3, respectively. Conclusions and implications: The effects of GF120918 on the distribution kinetics of morphine in the effect compartment were consistent with the distribution in brain extracellular fluid ( ECF) as estimated by intracerebral microdialysis. However, the time- course of morphine concentrations at the site of action in the brain, as deduced from the biophase model, is distinctly different from the brain ECF concentrations.
引用
收藏
页码:713 / 720
页数:8
相关论文
共 30 条
[1]  
Beal SL, 1999, NONMEM USERS GUIDE
[2]   Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats -: A microdialysis study [J].
Bouw, MR ;
Gårdmark, M ;
Hammarlund-Udenaes, M .
PHARMACEUTICAL RESEARCH, 2000, 17 (10) :1220-1227
[3]   Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats [J].
Chenel, M ;
Marchand, S ;
Dupuis, A ;
Lamarche, I ;
Paquereau, J ;
Pariat, C ;
Couet, W .
BRITISH JOURNAL OF PHARMACOLOGY, 2004, 142 (02) :323-330
[4]   Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats [J].
Cox, EH ;
VanHemert, JGN ;
Tukker, EJ ;
Danhof, M .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1997, 38 (02) :99-108
[5]  
Cox EH, 1998, J PHARMACOL EXP THER, V284, P1095
[6]   The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model [J].
Cox, EH ;
Langemeijer, MWE ;
Gubbens-Stibbe, JM ;
Muir, KT ;
Danhof, M .
ANESTHESIOLOGY, 1999, 90 (02) :535-544
[7]   Mechanism-based pharmacokinetic-pharmacodynamic modeling - A new classification of biomarkers [J].
Danhof, M ;
Alvan, G ;
Dahl, SG ;
Kuhlmann, J ;
Paintaud, G .
PHARMACEUTICAL RESEARCH, 2005, 22 (09) :1432-1437
[8]   Development and validation of a radioreceptor assay for the determination of morphine and its active metabolites in serum [J].
de Jong, LAA ;
Krämer, K ;
Kroeze, MPH ;
Bischoff, R ;
Uges, DRA ;
Franke, JP .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 39 (05) :964-971
[9]   PHARMACOKINETIC MODELING OF THE ANTICONVULSANT RESPONSE OF OXAZEPAM IN RATS USING THE PENTYLENETETRAZOL THRESHOLD CONCENTRATION AS PHARMACODYNAMIC MEASURE [J].
DINGEMANSE, J ;
SOLLIE, FAE ;
BREIMER, DD ;
DANHOF, M .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1988, 16 (02) :203-228
[10]   Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs [J].
Doan, KMM ;
Humphreys, JE ;
Webster, LO ;
Wring, SA ;
Shampine, LJ ;
Serabjit-Singh, CJ ;
Adkison, KK ;
Polli, JW .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) :1029-1037